These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Structural basis of respiratory syncytial virus neutralization by motavizumab.
    Author: McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD.
    Journal: Nat Struct Mol Biol; 2010 Feb; 17(2):248-50. PubMed ID: 20098425.
    Abstract:
    Motavizumab is approximately tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glycoprotein reveals the structural basis for this greater potency. Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed in a homologous structure.
    [Abstract] [Full Text] [Related] [New Search]